Steven LaFon is the Associate Director of the Anti-Viral Clinical research for Glaxo-Wellcome. He says he empathizes with Getty, and that the company's researchers are working as fast as they can to get the drug 15-92 to the marketplace. He says although the results of trials have been very encouraging, it is still in the very early stages of the approval and marketing process.
Copyright 1996 NPR
